Analyst consensus rating
PTC Therapeutics Analyst Rating: Buy
PTCT is rated Buy by 14 analysts with a $99.29 target. As of 2026-08-24.
Direct answer
PTC Therapeutics's consensus rating is Buy.
14 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $99.29.
Forecast evidence checked August 24, 2026.
Get free PTC Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $69.82
- Average price target
- $99.29
- High price target
- $130.00
- Low price target
- $70.00
- Low target gap
- +0.3%
- Target upside
- +42.2%
- High target gap
- +86.2%
- Target range width
- 85.9%
- Consensus rating
- Buy
- Analysts
- 14
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for PTC Therapeutics?
PTC Therapeutics has a verified Buy consensus. The same dataset has an average price target of $99.29.
How far are PTC Therapeutics's low and high targets from the recorded price?
The low target implies +0.3%, while the high target implies +86.2%.
How many analysts are included in PTC Therapeutics's consensus?
The verified consensus includes 14 analysts.
How is PTC Therapeutics's target upside or downside calculated?
The average target of $99.29 is divided by the recorded price of $69.82, then one is subtracted to produce +42.2%. This does not guarantee a future return.
When was PTC Therapeutics's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.